Bullish Prospects For Synthetic Biologics Inc. (AMEX: SYN) Shares In 2022

Synthetic Biologics Inc. (AMEX:SYN) price on Thursday, March 24, rose 1.88% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $0.35.

A look at the stock’s price movement, the close in the last trading session was $0.34, moving within a range at $0.33 and $0.39. The beta value (5-Year monthly) was 1.68. Turning to its 52-week performance, $0.74 and $0.22 were the 52-week high and 52-week low respectively. Overall, SYN moved 46.46% over the past month.

Synthetic Biologics Inc.’s market cap currently stands at around $46.41 million, with investors looking forward to this quarter’s earnings report slated for Mar 02, 2022 – Mar 07, 2022. Analysts project the company’s earnings per share (EPS) to be -$0.03, which has seen fiscal year 2021 EPS growth forecast to increase to -$0.18 and about -$0.11 for fiscal year 2022. Per the data, EPS growth is expected to be 72.70% for 2022 and 38.90% for the next financial year.

Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that SYN is a Hold. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.

2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 2 recommend SYN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.

SYN’s current price about 27.39% and 33.06% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 61.28, while 7-day volatility ratio is 24.32% and 14.95% in the 30-day chart. Further, Synthetic Biologics Inc. (SYN) has a beta value of 1.65, and an average true range (ATR) of 0.05. Analysts have given the company’s stock an average 52-week price target of $1.63, forecast between a low of $1.00 and high of $2.25. Looking at the price targets, the low is -185.71% off current price level while to achieve the yearly target high, price needs to move -542.86%. Nonetheless, investors will most likely welcome a -365.71% jump to $1.63 which is the analysts’ median price.

In the market, a comparison of Synthetic Biologics Inc. (SYN) and its peers suggest the former has performed considerably stronger. Data shows SYN’s intraday price has changed 1.88% in last session and -49.79% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 1.43% and 1.02% respectively in the last trading.

If we refocus on Synthetic Biologics Inc. (AMEX:SYN), historical trading data shows that trading volumes averaged 11.74 million over the past 10 days and 3.23 million over the past 3 months. The company’s latest data on shares outstanding shows there are 132.04 million shares.

The 1.76% of Synthetic Biologics Inc.’s shares are in the hands of company insiders while institutional holders own 10.40% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.39 million on Jan 30, 2022, giving us a short ratio of 0.88. The data shows that as of Jan 30, 2022 short interest in Synthetic Biologics Inc. (SYN) stood at 1.05% of shares outstanding, with shares short falling to 1.53 million registered in Dec 30, 2021. Current price change has pushed the stock 29.13% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the SYN stock continues to rise going into the next quarter.

Leave a Comment